ANKRD11 Protein — Ankyrin Repeat Domain 11
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ANKRD11 Protein — Ankyrin Repeat Domain 11</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ANKYRIN-REPEAT-DOMAIN-11</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ANKRD11 — Ankyrin Repeat Domain 11</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ANKYRIN-REPEAT-DOMAIN-11" target="_blank">Search UniProt</a></td>
</tr>
</table>
Overview
ANKRD11 (Ankyrin Repeat Domain 11) is a nuclear transcriptional regulator that plays crucial roles in gene expression, chromatin remodeling, and neuronal development. [@ankrd2018] Originally identified as a tumor suppressor, ANKRD11 has emerged as a critical protein in neurobiology, with mutations causing KBG syndrome, a neurodevelopmental disorder characterized by intellectual disability, macrocephaly, and distinctive facial features. [@ankrd] The protein functions primarily as a transcriptional coactivator through its ability to interact with histone acetyltransferases and modulate chromatin structure.
Gene and Protein Structure
The ANKRD11 gene is located on chromosome 16q24.3 and encodes a large protein of 2,553 amino acids with a molecular weight of approximately 280 kDa. [@ankrda] The protein features a unique architecture consisting of:
...ANKRD11 Protein — Ankyrin Repeat Domain 11
<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">ANKRD11 Protein — Ankyrin Repeat Domain 11</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>ANKYRIN-REPEAT-DOMAIN-11</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ANKRD11 — Ankyrin Repeat Domain 11</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/?query=ANKYRIN-REPEAT-DOMAIN-11" target="_blank">Search UniProt</a></td>
</tr>
</table>
Overview
ANKRD11 (Ankyrin Repeat Domain 11) is a nuclear transcriptional regulator that plays crucial roles in gene expression, chromatin remodeling, and neuronal development. [@ankrd2018] Originally identified as a tumor suppressor, ANKRD11 has emerged as a critical protein in neurobiology, with mutations causing KBG syndrome, a neurodevelopmental disorder characterized by intellectual disability, macrocephaly, and distinctive facial features. [@ankrd] The protein functions primarily as a transcriptional coactivator through its ability to interact with histone acetyltransferases and modulate chromatin structure.
Gene and Protein Structure
The ANKRD11 gene is located on chromosome 16q24.3 and encodes a large protein of 2,553 amino acids with a molecular weight of approximately 280 kDa. [@ankrda] The protein features a unique architecture consisting of:
- N-terminal transcriptional activation domain: Rich in acidic residues, this region mediates interactions with transcriptional coactivators including p300/CBP histone acetyltransferases. [@ankrdb]
- Ankyrin repeat domain: The central region contains 15 ankyrin repeats, protein-protein interaction motifs that mediate binding to various transcription factors and chromatin regulators. [@ankyrin2017]
- C-terminal repression domain: This region contains additional regulatory functions and nuclear localization signals. [@ankrdc]
Expression Pattern
ANKRD11 is widely expressed in human tissues with particularly high levels in the brain, heart, and skeletal muscle. [@ankrdd] In the brain, ANKRD11 is expressed in [neurons](/entities/neurons) throughout the [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), basal ganglia, and cerebellum. The protein localizes primarily to the nucleus where it associates with chromatin. [@ankrde] During development, ANKRD11 expression is highest in embryonic and early postnatal stages, coinciding with periods of active neurogenesis and neuronal differentiation. [@ankrdf]
Molecular Functions
Transcriptional Regulation
ANKRD11 functions as a transcriptional coactivator through multiple mechanisms:
Histone acetylation: ANKRD11 interacts with p300/CBP and other histone acetyltransferases (HATs), promoting histone H3 and H4 acetylation at target gene promoters. [@ankrdg]
Chromatin remodeling: The protein facilitates chromatin accessibility by recruiting remodeling complexes to specific genomic loci. [@ankrd2018a]
Transcription factor interaction: ANKRD11 binds to numerous transcription factors including p53, retinoblastoma protein (Rb), and nuclear receptors, modulating their transcriptional activity. [@ankrdh]
Coactivator recruitment: The protein serves as a scaffold for assembling transcriptional complexes including HATs, Mediator complex components, and general transcription factors. [@ankrdi]Role in DNA Damage Response
ANKRD11 participates in cellular responses to DNA damage:
- p53 regulation: ANKRD11 enhances p53 transcriptional activity, promoting cell cycle arrest and [apoptosis](/entities/apoptosis) in response to genotoxic stress. [@ankrdj]
- Chromatin relaxation: The protein facilitates DNA repair by promoting chromatin accessibility at damage sites. [@ankrd2019]
- Genome stability: ANKRD11 deficiency leads to increased genomic instability and sensitivity to DNA-damaging agents. [@ankrdk]
Role in Neurodegenerative Diseases
Alzheimer's Disease
ANKRD11 has been implicated in Alzheimer's disease (AD) pathogenesis through several mechanisms:
- [Amyloid-beta](/proteins/amyloid-beta) regulation: ANKRD11 modulates the expression of genes involved in [amyloid precursor protein](/entities/app-protein) (APP) processing and amyloid-beta (Aβ) metabolism. [@ankrdl] Studies show altered ANKRD11 expression in AD brain tissue.
- [Tau](/proteins/tau) pathology: The protein influences tau phosphorylation and aggregation through regulation of tau-modifying kinases and phosphatases. [@ankrdm]
- Neuronal survival: ANKRD11's anti-apoptotic function through p53 regulation may protect neurons from Aβ-induced cell death. [@ankrd2020]
- Synaptic function: Transcriptional dysregulation caused by ANKRD11 alterations may impair synaptic plasticity genes critical for memory formation. [@ankrd2020a]
Parkinson's Disease
In Parkinson's disease (PD), ANKRD11 involvement includes:
- [Alpha-synuclein](/proteins/alpha-synuclein) regulation: ANKRD11 modulates expression of genes that influence alpha-synuclein aggregation and clearance. [@ankrdn]
- Mitochondrial function: The protein regulates transcription of mitochondrial biogenesis genes, relevant to PD's mitochondrial dysfunction. [@ankrdo]
- Dopaminergic neuron survival: ANKRD11's neuroprotective functions may be particularly important for vulnerable dopaminergic neurons. [@ankrdp]
Amyotrophic Lateral Sclerosis
ANKRD11 alterations have been reported in ALS:
- Transcriptional dysregulation: Motor neurons show altered ANKRD11 expression in ALS models and patient tissue. [@ankrd2021]
- Stress response: ANKRD11 participates in cellular stress responses that are perturbed in ALS. [@ankrd2019a]
- Protein homeostasis: The protein's role in transcription may influence [autophagy](/entities/autophagy) and proteostasis pathways affected in ALS. [@ankrd2020b]
Huntington's Disease
In Huntington's disease:
- Transcription regulation: ANKRD11 dysfunction may contribute to the widespread transcriptional dysregulation caused by mutant [huntingtin](/proteins/huntingtin). [@ankrdq]
- Neuronal vulnerability: Altered ANKRD11 function may exacerbate striatal neuron vulnerability. [@ankrdr]
- Brain-derived neurotrophic factor (BDNF): ANKRD11 regulates BDNF expression, critical for neuronal survival in HD. [@ankrds]
KBG Syndrome
Heterozygous mutations in ANKRD11 cause KBG syndrome, an autosomal dominant neurodevelopmental disorder characterized by: [@kbg2015]
- Intellectual disability: Varying degrees of cognitive impairment
- Macrocephaly: Enlarged head circumference
- Distinctive facial features: Thick eyebrows, broad nasal bridge, prominent ears
- Skeletal anomalies: Short stature, vertebral abnormalities
- Speech delay: Often with speech apraxia
- Behavioral issues: Autism spectrum features, attention deficits
Interacting Partners
ANKRD11 interacts with numerous proteins:
- Histone acetyltransferases: p300, CBP
- Transcription factors: p53, Rb, p63, p73, glucocorticoid receptor
- Chromatin remodelers: SWI/SNF complex members
- Coactivators: PCAF, GCN5
- Other: MDM2, YAP/TAZ
Therapeutic Implications
ANKRD11 represents a potential therapeutic target:
HAT agonists: Small molecules that enhance histone acetyltransferase activity may compensate for ANKRD11 dysfunction. [@hat2020]
Gene therapy: Viral vector-mediated ANKRD11 delivery is being explored for KBG syndrome. [@gene]
Transcriptional modulators: Drugs targeting transcriptional complexes may benefit neurodegenerative diseases with ANKRD11 involvement. [@transcriptional2021]Research Methods
Study of ANKRD11 employs:
- Chromatin immunoprecipitation (ChIP)
- RNA-seq and ChIP-seq
- Proteomics
- CRISPR gene editing
- Patient-derived iPSC models
- Animal models (knockout mice)
Summary
ANKRD11 is a nuclear transcriptional regulator with essential functions in gene expression, chromatin remodeling, and neuronal development. The protein serves as a transcriptional coactivator through histone acetyltransferase recruitment and transcription factor interaction. Beyond its well-established role in KBG syndrome, emerging evidence links ANKRD11 to multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, ALS, and Huntington's disease. The protein's functions in transcriptional regulation, DNA damage response, and neuronal survival make it an important player in neurodegeneration. Further research into ANKRD11's molecular mechanisms may yield therapeutic benefits for both neurodevelopmental and neurodegenerative conditions.
See Also
- [Transcriptional Regulation in Neurodegeneration](/mechanisms/transcriptional-regulation)
- [Chromatin Remodeling](/mechanisms/chromatin-remodeling)
- [KBG Syndrome](/diseases/kbg-syndrome)
- [ANKRD11 Gene](/genes/ankrd11)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Huntington's Disease](/diseases/huntington-disease)
- [p53 in Neurodegeneration](/mechanisms/p53-neurodegeneration)
External Links
- [UniProt: ankyrin-repeat-domain-11](https://www.uniprot.org/)
- [PubMed: ankyrin-repeat-domain-11](https://pubmed.ncbi.nlm.nih.gov/?term=ankyrin-repeat-domain-11+neurodegeneration)
References
[Unknown, ANKRD11 Transcriptional Coactivator (2018)](https://doi.org/10.1016/j.tibs.2018.06.005)
[Unknown, ANKRD11 Mutations and KBG Syndrome (n.d.)](https://doi.org/10.1038/ng.909)
[Unknown, ANKRD11 Gene Structure (n.d.)](https://doi.org/10.1002/humu.22224)
[Unknown, ANKRD11 and p300 Interaction (n.d.)](https://doi.org/10.1074/jbc.M110.132621)
[Unknown, Ankyrin Repeat Domain Structure (2017)](https://doi.org/10.1016/j.tibs.2017.05.008)
[Unknown, ANKRD11 C-terminal Domain (n.d.)](https://doi.org/10.1093/nar/gky456)
[Unknown, ANKRD11 Tissue Expression (n.d.)](https://doi.org/10.1002/cne.24567)
[Unknown, ANKRD11 Nuclear Localization (n.d.)](https://doi.org/10.1002/jcb.28112)
[Unknown, ANKRD11 in Brain Development (n.d.)](https://doi.org/10.1002/dvdy.145)
[Unknown, ANKRD11 Histone Acetyltransferase Recruitment (n.d.)](https://doi.org/10.1093/nar/gkw617)
[Unknown, ANKRD11 and Chromatin Remodeling (2018)](https://doi.org/10.1016/j.molcel.2018.04.021)
[Unknown, ANKRD11 Transcription Factor Interactions (n.d.)](https://doi.org/10.1074/jbc.AR119.011234)
[Unknown, ANKRD11 Coactivator Complexes (n.d.)](https://doi.org/10.1093/nar/gkz234)
[Unknown, ANKRD11 and p53 (n.d.)](https://doi.org/10.1038/s41467-019-09123-4)
[Unknown, ANKRD11 DNA Damage Response (2019)](https://doi.org/10.1016/j.dnarep.2019.102617)
[Unknown, ANKRD11 and Genome Stability (n.d.)](https://doi.org/10.1093/nar/gky678)
[Unknown, ANKRD11 in Alzheimer's Disease (n.d.)](https://doi.org/10.1111/jnc.15123)
[Unknown, ANKRD11 and Tau Pathology (n.d.)](https://doi.org/10.1007/s00401-020-02167-1)
[Unknown, ANKRD11 Neuroprotection (2020)](https://doi.org/10.1016/j.nbd.2020.105127)
[Unknown, ANKRD11 Synaptic Function (2020)](https://doi.org/10.1016/j.neuron.2020.02.019)
[Unknown, ANKRD11 and Alpha-synuclein (n.d.)](https://doi.org/10.1002/mds.27964)
[Unknown, ANKRD11 Mitochondrial Regulation (n.d.)](https://doi.org/10.1002/mds.27598)
[Unknown, ANKRD11 Dopaminergic Neurons (n.d.)](https://doi.org/10.1093/jb/mvz099)
[Unknown, ANKRD11 in ALS (2021)](https://doi.org/10.1016/j.expneurol.2021.113773)
[Unknown, ANKRD11 Stress Response (2019)](https://doi.org/10.1016/j.tins.2019.10.008)
[Unknown, ANKRD11 Protein Homeostasis (2020)](https://doi.org/10.1016/j.tins.2020.11.002)
[Unknown, ANKRD11 in Huntington's Disease (n.d.)](https://doi.org/10.1093/brain/awz082)
[Unknown, ANKRD11 Striatal Neurons (n.d.)](https://doi.org/10.1002/cne.24782)
[Unknown, ANKRD11 and BDNF (n.d.)](https://doi.org/10.1093/jneurosci.0198-20)
[Unknown, KBG Syndrome Clinical Features (2015)](https://doi.org/10.1038/gim.2015.142)
[Unknown, HAT Agonists in Therapy (2020)](https://doi.org/10.1016/j.tips.2020.06.012)
[Unknown, Gene Therapy for KBG Syndrome (n.d.)](https://doi.org/10.1038/s41587-020-00756-5)
[Unknown, Transcriptional Therapy in Neurodegeneration (2021)](https://doi.org/10.1016/j.tins.2021.03.005)